diabetestalk.net

Smart Lifestyle & Dietary Hacks To Control Diabetes

Smart Lifestyle & Dietary Hacks to Control Diabetes

Smart Lifestyle & Dietary Hacks to Control Diabetes


Did you know that 246 million people in the world, today, are living with diabetes? This is almost 6% of the worlds adult population. It is estimated that currently there are about 40 million people with diabetes in India & by the year of 2025, this number will increase to 70 million. This would mean that every 5th diabetic in the world would be an Indian. Dont you think these numbers are alarming? What are we actually doing to save ourselves from this havoc condition? Its not only about you, but its about the health of your family as well!
Diabetes also increases the risk of suffering from a heart disease, in addition to developing mental health disorders such as depression, etc. There are typically two types of diabetes conditions known to medical science
Type 1 Diabetes An autoimmune condition, it occurs when the immune system of the body mistakenly attacks and damages its own cells that produce insulin. Usually, the attack happens in response to environmental or genetic factors. Lifestyle factors also trigger Type 1 diabetes in many individuals.
Type 2 Diabetes Its a more common type of diabetes than its counterpart. The condition takes place when the body starts to resist insulin. This, in turn, makes the pancreas produce more insulin until its unable to keep pace with the demand. Decreased production of insulin increases blood sugar level and hence, the condition develops. However, curing Type 2 diabetes is easier than Type 1 disease.
With diabetes comes a list of precautions, especially in terms of what you can eat and drink. But, the good news is that, with Continue reading

Rate this article
Total 1 ratings
Top 10 Online Resources for People with Diabetes

Top 10 Online Resources for People with Diabetes


Top 10 Online Resources for People with Diabetes
Online communities, networks, and publications can be a great source of information for both people newly diagnosed with diabetes, and also for people who have been living with diabetes for a while. Below are some of our favorite websites and online resources for finding support and learning about diabetes.
This online magazine features insights on everything diabetes-related including lifestyle, products & tech, recipes, nutrition, and overall health. We love the articles here and how diverse the content is. Some of our favorite posts include:
Emergency Preparedness Guide for People with Diabetes
diaTribe is an online publication with articles geared at helping peoplemake sense of diabetes.The site features resources for Type 1 and Type 2 Diabetes, and discusses everything from mental health to recipes to technology products. Some of our recent favorite articles include:
Since 2004, dLife has been a platform for people to more about diabetes and connect with other diabetes consumers, patients, and caregivers. Theyre articles and resources are highly comprehensive, including the following resources:
JDRFis the leading global organization funding type 1 diabetes (T1D) research. Their organization does incredible work in the community, hosting a myriad of local events. Apart from the research they fund, they have a highly comprehensive compendium of resources and informational documents. Some of our favorite resources are:
T1D Connection Program : Get support and connect with a volunteer and discuss your questions and Continue reading

Early prediction of autoimmune (type 1) diabetes

Early prediction of autoimmune (type 1) diabetes


, Volume 60, Issue8 , pp 13701381 | Cite as
Early prediction of autoimmune (type 1) diabetes
Underlying type 1 diabetes is a genetic aetiology dominated by the influence of specific HLA haplotypes involving primarily the class II DR-DQ region. In genetically predisposed children with the DR4-DQ8 haplotype, exogenous factors, yet to be identified, are thought to trigger an autoimmune reaction against insulin, signalled by insulin autoantibodies as the first autoantibody to appear. In children with the DR3-DQ2 haplotype, the triggering reaction is primarily against GAD signalled by GAD autoantibodies (GADA) as the first-appearing autoantibody. The incidence rate of insulin autoantibodies as the first-appearing autoantibody peaks during the first years of life and declines thereafter. The incidence rate of GADA as the first-appearing autoantibody peaks later but does not decline. The first autoantibody may variably be followed, in an apparently non-HLA-associated pathogenesis, by a second, third or fourth autoantibody. Although not all persons with a single type of autoantibody progress to diabetes, the presence of multiple autoantibodies seems invariably to be followed by loss of functional beta cell mass and eventually by dysglycaemia and symptoms. Infiltration of mononuclear cells in and around the islets appears to be a late phenomenon appearing in the multiple-autoantibody-positive with dysglycaemia. As our understanding of the aetiology and pathogenesis of type 1 diabetes advances, the improved capability for early prediction should guide new strategies for the preve Continue reading

Metformin: clinical use in type 2 diabetes

Metformin: clinical use in type 2 diabetes


, Volume 60, Issue9 , pp 15861593 | Cite as
Metformin: clinical use in type 2 diabetes
Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there still remains controversy regarding the drugs precise mechanism of action, which is thought to involve a reduction in hepatic glucose production. It is now recommended as first-line treatment in various guidelines, including that of the EASD and ADA. Its favoured status lies in its efficacy, low cost, weight neutrality and good safety profile. Other benefits have also been described, including improvements in certain lipids, inflammatory markers, and a reduction in cardiovascular events, apparently independent from the drugs glucose-lowering effect. Data have emerged questioning the previous reluctance to use this agent in those with mild to moderate chronic kidney disease. Regulations guiding its use in patients with stable, modest renal dysfunction have, as a result, become more lenient in recent years. With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more robust evidence for cardioprotection, metformins established role as foundation therapy in type 2 diabetes may justifiably be challenged.
BiguanidesGlucose-lowering therapyMetforminReviewType 2 diabetes mellitus
Diabetes Prevention Program Outcomes Study
The online version of this article (doi: 10.1007/s00125-017-4336-x ) contains a slideset of the figures for download, which is available to auth Continue reading

Diabetes Drug Can Now Be Used to Treat Obesity

Diabetes Drug Can Now Be Used to Treat Obesity


Diabetes Drug Can Now Be Used to Treat Obesity
Researchers say liraglutide, which is sold as both Victoza and now Saxenda, can be used to help with weight loss as well as type 2 diabetes.
More than one-third of the United States population qualifies as obese.
That means the pursuit for a pharmaceutical weight loss drug has only become more intense.
And theres some encouraging news on this front.
A recently published study from the Mayo Clinic reports that a pharmaceutical weight loss drug already exists and has proven to be effective, even in those who are obese.
Liraglutide is a prescription medication that is self-administered via injection once per day.
It was originally created to treat type 2 diabetes under the brand name Victoza , manufactured by Novo Nordisk.
Our paper shows that liraglutide, administered for 3 months at the approved dose of 3 milligrams per day, was associated with an average weight loss of 12 pounds compared to an average 6.6-pound weight loss for patients receiving a placebo, explained Dr. Michael Camilleri, a gastroenterologist at Mayo Clinic and a senior author of the study.
In order to prescribe this medication specifically for weight loss, healthcare providers encountered an obstacle.
Insurance companies would only cover Victoza for people with an indication of diabetes or prediabetes.
Being obese does not necessarily mean a person has diabetes, so theres a hurdle to jump in order to prescribe the drug for weight loss.
Consequently, Novo Nordisk rebranded liraglutide as Saxenda and categorized it as a weight loss drug, resulting Continue reading

No more pages to load

Popular Articles

Related Articles